We would like to thank Efthimiadis et al. for their interest in our work. Indeed, it was long believed that patients with hypertrophic cardiomyopathy (HCM) had normal or supranormal systolic function despite mutations in genes encoding for sarcomeric proteins. This concept was, at least partly, based on the use of endocardial indices of systolic function such as ejection fraction. Ejection fraction is generally normal or supranormal in HCM patients. However, it is well known that ejection fraction is a poor surrogate for systolic function in the presence of left ventricular hypertrophy because a normal ejection fraction is maintained by the subnormal function of additional sarcomeres laid in parallel. Reduced shortening of extra parallel sarcomeres leads to the same thickening and ejection of blood as would normal shortening of fewer sarcomeres. 1 Experimental data started to separate reality from myth by showing that there is myocardial dysfunction even before the development of left ventricular hypertrophy. 2 Whether this is detectable in the in vivo heart remains a difficult task. Follow up studies looking at young subjects with mutations before the development of hypertrophy may give the answer to this elusive question. We concur that isolated systolic or diastolic dysfunction do not exist. One is coupled to the other. Studies have confirmed that parameters of systolic function are important determinants of early diastolic function. 3 The sensitivity of the techniques used to assess function seems to play a crucial role in detecting subtle abnormalities. 4 Interestingly, in our study, patients with HCM had myocardial shortening and thickening persisting well after aortic valve closure in the more hypertrophied basal septal myocardial segments. This was associated with reduced early diastolic myocardial velocity in those myocardial segments suggesting abnormal myocardial relaxation. The reduction in systolic myocardial deformation was associated not only with maximal end-diastolic wall thickness and decreased exercise capacity but also with a blunted blood pressure response with exercise (r ¼ 0.62, P , 0.01). Given a blunted blood pressure response is a predictor of poor outcome in patients with HCM; this finding suggests that the abnormalities in myocardial deformation may be used to predict exercise capacity and may help risk stratify patients with HCM.
Certainly, non-invasive techniques have helped us uncover some secrets of the hypertrophic heart. We hope that future studies will tell us more about when, how, and why hypertrophy as well as myocardial dysfunction ensue in HCM. Non-compaction: a distinct cardiomyopathy or nonspecific morphological trait?
Javier Ganame
With great interest, we have read the article of Hoedemaekers et al.
1 on linking non-compaction cardiomyopathy to hypertrophic, restrictive, and dilated cardiomyopathies. The authors extensively describe two families in which variable severities of non-compaction of the myocardium segregated with mutations in the cardiac ß myosin heavy chain gene (MYH7). Although genetic heterogeneity of traditional cardiomyopathies is well recognized, the identification of non-compaction in patients with dilated, hypertrophic, and restrictive cardiomyopathies suggests that non-compaction may be considered as a nonspecific morphological trait rather than a distinct cardiomyopathy. 2 In addition, not all non-compaction associated mutations are confined to genes that encode for a specific construct or functional element of the cardiomyocyte, but have been described in genes that encode for sarcomeric, cytoskeletal, and/or cell junctional proteins. 1 Also, the genetic heterogeneity of noncompaction may reflect non-specificity of the current criteria for its diagnosis. According to Jenni et al., 3 isolated non-compaction cardiomyopathy is diagnosed with echocardiography when the following criteria are met: (i) coexisting cardiac abnormalities are absent, (ii) the left ventricular wall has a twolayered structure with a non-compacted to compact layer ratio .2 in end-systole, (iii) the trabecular non-compacted meshwork is predominantly located in the apical, lateral, and inferior regions of the left ventricle, and (iv) colour Doppler evidence of deep perfused intertrabecular recesses is present. While left ventricular trabeculae are more easily observed with high resolution imaging techniques such as cardiac magnetic resonance, Petersen et al. 4 proposed to use a noncompacted to compact layer ratio .2.3 in end-diastole as a cut-off value to diagnose left ventricular non-compaction cardiomyopathy.
In the echocardiographic study from Hoedemaekers et al., only the second and forth criteria of Jenni et al. were used to diagnose non-compaction cardiomyopathy and 'mild' forms were also noted. These modifications of diagnostic criteria will most likely have introduced increased susceptibility to overdiagnosis in this study. Whether the described mutations encode for a pure form of noncompaction cardiomyopathy is therefore debatable.
In general, non-specific definition and/or limited imaging quality may lead to avoidable misinterpretation of cardiac morphology. 5 When available, we advocate to use imaging modalities with optimal resolution for more adequate definition of cardiomyopathies in linkage studies, which may give an answer to the question whether non-compaction can be considered as a distinct cardiomyopathy or as non-specific morphological trait. Non-compaction: a distinct cardiomyopathy or nonspecific morphological trait?: reply
With great interest I read the letter by Germans et al., as a reaction to our manuscript titled 'cardiac b-myosin heavy chain defects in two families with noncompaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive and dilated cardiomyopathies', describing two large noncompaction cardiomyopathy (NCCM) families with b-myosin heavy chain (MYH7) mutations. 1 Germans et al. comment that we used only two of the four diagnostic criteria for NCCM and that the use of non-specific definitions and a method of limited imaging quality (echocardiography) in these two NCCM families likely lead to misinterpretation of cardiac morphology and over diagnosis. Subsequently they suggest that cardiac magnetic resonance should be used to determine whether NCCM can be considered a distinct cardiomyopathy or as a non-specific morphological trait.
Echocardiography is considered the reference standard for the diagnosis of NCCM. For the standardization of this diagnosis, four clear-cut echocardiographic criteria (the so-called Jenni criteria) were established and validated in larger series of patients and pathological samples. 2 Recently, Petersen et al., 3 using a limited number of seven NCCM patients, developed diagnostic NCCM criteria for the use with MRI instead of echocardiography. They determined that for MRI studies the ratio of non-compacted to compacted myocardium should be .2.3 in diastole to accurately distinguish pathological non-compaction. The higher value of this ratio, when compared with the echocardiographic Jenni-ratio (of .2) to be taken in systole, reflects that the former is determined in diastole. 3 For the identification of two large families with NCCM, we used the Jenni diagnostic criteria lege artis, without any modification as is suggested by Germans et al. These authors most likely failed to notice the diagnosisparagraph in the Methods section explicitly stating the compliance to all four diagnostic Jenni criteria for a diagnosis of NCCM. In both families, we identified multiple patients that fulfilled these diagnostic NCCM criteria. The presence, in family B, of one asymptomatic 11-year-old boy with only mild apical NCCM, as was commented on by Germans et al., most likely reflects partial expression of pathological NCCM. This phenomenon is typical of autosomal dominant conditions and has been reported before in families with NCCM. 3, 4 The discussion whether NCCM is indeed a distinct cardiomyopathy or a non-specific morphological trait has been ongoing, where the latter view is exemplified by the Biagini paper 5 (wrongly cited by Germans et al.,
correct citation below). Morphological, aetiological and genetic data should be used to gain insight into the pathophysiology of NCCM. Cardiac imaging physicians should be aware of morphological over diagnosis and classification since imaging techniques, whether echocardiography, MRI, ultrasound or CT, may describe various manifestations of the same cardiomyopathy spectrum and the heterogeneous clinical expression may be an example of this phenomenon. The identification of MYH7 defects in HCM, DCM, RCM, and NCCM 1 suggests partial common pathophysiological mechanisms for all morphologically classified cardiomyopathies. In fact, the identification of non-compaction-like crypts in asymptomatic HCM mutation carriers by Germans et al. 6 supports this very suggestion.
